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Abstract
Background: The timely and accurate diagnosis of specific influenza virus strains is crucial to effective prophylaxis,
vaccine preparation and early antiviral therapy. The detection of influenza A viruses is mainly accomplished using
polymerase chain reaction (PCR) techniques or antibody-based assays. In conjugation with the immunoassay
utilizing monoclonal antibody, mass spectrometry is an alternative to identify proteins derived from a target
influenza virus. Taking advantage of the large surface area-to-volume ratio, antibody-conjugated magnetic
nanoparticles can act as an effective probe to extract influenza virus for sodium dodecylsulfate polyacrylamide gel
electrophoresis (SDS-PAGE) and on-bead mass spectrometric analysis.
Results: Iron oxide magnetic nanoparticles (MNP) were functionalized with H5N2 viral antibodies targeting the
hemagglutinin protein and capped with methoxy-terminated ethylene glycol to suppress nonspecific binding. The
antibody-conjugated MNPs possessed a high specificity to H5N2 virus without cross-reactivity with recombinant
H5N1 viruses. The unambiguous identification of the captured hemagglutinin on magnetic nanoparticles was
realized by SDS-PAGE visualization and peptide sequence identification using liquid chromatography-tandem mass
spectrometry (LC-MS/MS).
Conclusions: The assay combining efficient magnetic separation and MALDI-MS readout offers a rapid and
sensitive method for virus screening. Direct on-MNP detection by matrix-assisted laser desorption/ionization time-
of-flight mass spectrometry (MALDI-TOF MS) provided high sensitivity (~10
3 EID50 per mL) and a timely diagnosis
within one hour. The magnetic nanoparticles encapsulated with monoclonal antibodies could be used as a specific
probe to distinguish different subtypes of influenza.
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Background
Influenza remains a major health problem for humans
and animals. The recent cross-species transmission of
avian influenza viruses to humans has raised a great
concern for the possible global pandemic threat if the
viruses become transmissible among humans.
Influenza viruses can be classified into types A, B and
C. These subtypes are further designated according to
the serological cross-reactivity of the antibodies against
hemagglutinin (HA) and neuraminidase (NA), which are
the most important glycoproteins on the surface of
influenza virus with critical roles in virus infection and
transmission. To date, 16 HA (H1-H16) and 9 NA (N1-
N9) subtypes in influenza A viruses have been isolated
from avian species. HA is translated as a single polypro-
tein, HA0, which exists in a trimeric assembly [1,2]. The
transmembrane protein HA0 consists of two polypeptide
chains, HA1 and HA2, linked by inter-chain disulfide
bonds. For viral activation, HA0 m u s tu n d e r g oa ne n z y -
matic cleavage to give two functional subunits, HA1 and
HA2 [1,2]. Highly pathogenic avian influenza viruses,
such as H5N1, contain many basic amino acid residues
in the cleavage site of HA0 and are thus easily activated
by trypsin and other proteases for systemic infection
[1,2].
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phylaxis and treatment [3-5]: amantadine and rimanta-
dine act as M2 ion channel blockers, and Tamiflu™
(the phosphate salt of oseltamivir) and Relenza™ (zana-
mivir) inhibit the activity of NA. For the most effective
treatment, these anti-influenza drugs are recommended
for use within 48 h of the onset of influenza symptoms
because proliferation of the virus reaches a peak after 2
days of infection. Thus, timely and accurate diagnosis of
specific influenza virus strains is crucial for effective
prophylaxis, vaccine preparation and early antiviral
therapy.
The detection of influenza A viruses is mainly accom-
plished using polymerase chain reaction (PCR) techni-
ques or antibody-based assays to identify the relatively
abundant nucleoproteins (NP) [6-13]. Because NP is
only a type-specific protein, subtype- or strain-specific
diagnosis cannot be achieved. For the specific detection
of influenza viruses using real-time reverse transcrip-
tion-polymerase chain reaction (rRT-PCR) [6-9], choos-
ing proper primer pairs for subtyping becomes critical.
Although sequence-based diagnosis often shows high
sensitivity, the experimental procedures are tedious and
may give false results.
According to a recent survey [8], the commercially
available influenza diagnostic kits based on rRT-PCR
can be used to detect H1N1 virus with a limit of detec-
tion in the range of 10
4.5-10
5.5 TCID50 (50% tissue cul-
ture infective dose) per mL. However, a negative result
does not rule out possible infection with influenza virus
due to the overall low sensitivity (40-69%) of the diag-
nostic kits [8]. In contrast, an antigen capture immu-
noassay with specific monoclonal antibodies [10-13] is
often utilized in rapid influenza diagnostic tests. An
investigation into the commercially available test kits
indicated that 10
4.7 mean embryo lethal dose (ELD50)/
mL of avian influenza viruses in allantoic fluid can be
detected by an antigen capture immunoassay [10].
The low sensitivity in antigen tests may be proble-
matic in dealing with untreated samples due to nonspe-
cific interactions with other proteins. The antigen-
capture enzyme-linked immunosorbent assay (ELISA)
has been explored to distinguish subtypes of influenza
viruses with better sensitivity than immunoassays [11].
However, ELISA is time consuming and usually takes
prolonged times (~ 12 hours) to provide results.
Alternative methods have been investigated for viral
detection, including surface plasmon resonance [14],
multiplexed flow cytometry [15], quartz-crystal microba-
lance [16], mass spectrometry [17-19], and microarrays
[20-26]. With the power of peptide sequencing and
database searches for unknown protein identification,
however, mass spectrometry has been considered as one
of the gold standard methods for protein analysis due to
its low detection limit, rich structural information, and,
most importantly, high accuracy. The Yip group was
one of the first to integrate affinity capture techniques
with direct mass spectrometric detection of target pro-
teins from a complex mixture [27]. The concept was
advanced further by Nelson and coworkers in the devel-
opment of a mass spectrometric immunoassay (MSIA)
using affinity pipette tips to selectively detect proteins
and their variants [28-30]. Despite these existing meth-
odologies, to our knowledge the application of affinity-
based mass spectrometric methods for detection and
identification of flu strains remains unexplored.
In combination with immunoassays utilizing monoclo-
nal antibodies, mass spectrometry is especially useful for
the identification of proteins derived from a target influ-
enza virus. Mass spectrometry is not only applicable to
confirm the subtype of virus but is also a powerful tool
for the identification of the antigenic determinants on
the viral HA [17-19]. Prior enrichment of the viral anti-
gen is often utilized to improve the detection sensitivity
and the coverage of peptide sequence identification in
the mass spectra. An effective method for viral antigen
enrichment using surface functionalized magnetic nano-
particles is pursued in this study.
Taking advantage of the large surface area-to-volume
ratio and the unique chemical and physical properties of
nanoparticles, a considerable number of studies on sur-
face functionalization have been reported for biomedical
applications. Among the various types of nanoparticles,
magnetic nanoparticles (MNPs) have attracted increas-
ing attention for the advantage of efficient separation
from complex mixtures with a magnetic field [31-39].
This unique characteristic of MNPs surpasses traditional
solvent intensive and time-consuming purification
methods.
As demonstrated in our previous study [36,37], anti-
body-conjugated MNPs with proper surface protection
act as efficient affinity probes for the rapid extraction of
target proteins from human plasma. Because HA pro-
teins are located on the surface of influenza viruses,
MNPs modified with HA antibodies can be envisioned
as an effective nanosensor for rapid detection of influ-
enza viruses. Through this MNP-assisted mass spectro-
metry-based immunoassay, we expect to develop a
simple and fast virus screening assay with unambiguous
identification. H5N2, an avian influenza virus with low
pathogenicity, and recombinant H5N1 pseudo-viruses
were utilized as proof-of-concept model systems to eval-
uate the assay performance in terms of sensitivity and
specificity. The data demonstrated the combined use of
the antibody-MNP and MALDI-MS methods for the
sensitive detection of influenza viruses and rapid screen-
ing of virus subtypes. The specificity of HA enrichment
was confirmed by sodium dodecylsulfate polyacrylamide
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sequencing using liquid chromatography-tandem mass
spectrometry (LC-MS/MS).
Results and discussion
￿ Preparation and characterization of ethyleneglycol-
protected anti-HA antibody-conjugated magnetic
nanoparticles
The synthetic scheme for the antibody-conjugated
MNPs is detailed in Figure 1A. The iron oxide nanopar-
ticles (Fe3O4) were prepared by mixing FeCl2 and FeCl3
under basic conditions according to the previously
reported procedure [40]. Through treatment with 3-ami-
nopropyltrimethoxysilane (APS), the aminosilane coated
MNPs (AS@Fe3O4 MNPs) exhibited an increased stabi-
lity and contained amino groups for surface functionali-
zation. The direct cross-linking of antibody with the
AS@Fe3O4 MNPs was achieved through activation with
a bifunctional linker, suberic acid bis(N-hydroxysuccini-
mide) ester (DSS), followed by incubation with the
H5N2-specific monoclonal antibodies [41]. Compared
with conventional approaches using protein G or pro-
tein A for antibody immobilization, direct conjugation
was chosen to avoid non-specific association arising
from protein A-conjugated MNPs. Because of the pre-
sence of other abundant non-antigenic proteins in the
allantoic fluid, we noted that proper surface blocking of
the MNPs was essential to avoid nonspecific interac-
tions, which seriously compete with specific nanoprobe-
virus recognition. Thus, further surface capping with an
optimized concentration of methoxy-terminated ethy-
lene-glycol amine (MEGA) was conducted to give the
desired antibody-conjugated MNPs (designated as
AbH5N2@Fe3O4 MNPs). The MEGA-capped AbH5N2@-
Fe3O4 MNPs were washed with phosphate buffered sal-
ine (PBS, pH 7.4) and stored at 4°C for months without
loss of activity.
The synthesized AS@Fe3O4 MNPs exhibited a spheri-
cal shape with an average diameter of ~90 ± 30 nm, as
seen in transmission electron microscopy (Figure 2A).
The spinel structure of AS@Fe3O4 MNP was revealed
by powder X-ray diffraction (Figure 2B), which showed
Figure 1 Preparation of MEG-protected anti-HA antibody-conjugated magnetic nanoparticles for isolation and detection of HA
proteins.
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(311), (400), (422), (511) and (440) [42]. The AS@Fe3O4
MNP was superparamagnetic at room temperature (Fig-
u r e2 C ) ,a se v i d e n c eb yi t sh y s t e r e s i sl o o pi ns u p e r c o n -
ducting quantum interference device magnetometer
(SQUID) (i.e., the magnetization reached saturation in
an external magnetic field, but the magnetic character
diminished in the absence of an external magnetic field).
The unique superparamagnetic property of AS@Fe3O4
MNPs allowed easy magnetic separation from a complex
mixture during synthesis or incubation.
￿ Extraction of HA proteins by antibody-conjugated
magnetic nanoparticles and on-bead MALDI-MS analysis
Our strategy for isolation and identification of HA pro-
teins by AbH5N2@Fe3O4 MNP is depicted in Figure 1B.
Briefly, the AbH5N2@Fe3O4 MNPs were incubated with
virus lysate in a chosen buffer. After incubation, the
newly formed complexes containing AbH5N2@Fe3O4
MNPs and extracted HA (designated as HA-MNP com-
plexes) were readily isolated by applying a magnet. The
nonspecifically bound proteins were washed away, and
the HA-MNP complexes were directly analyzed by
either SDS-PAGE or MALDI-TOF MS. It was noted
that both assays could be performed in an efficient man-
ner without commonly required elution and desalting;
our method thus reduced the time required for assay.
It was also noted that the incubation buffer was cru-
cial to this experiment. Virus lysate in allantoic fluid has
a complex composition, containing not only the H5N2
virus, but also other proteins abundant in the culture
medium. Non-specific adsorption from these abundant
proteins often interferes with immunoassays. Further-
more, HA is a trimeric transmembrane protein; thus
detergent or salts are required to properly solubilize the
hydrophobic protein and to avoid protein-protein aggre-
gation. The effect of using different buffers on the
specificity of affinity extraction was therefore evaluated.
RIPA buffer, which is commonly used as a lysis buffer
for immunoprecipitation assays, showed the best
removal of abundant proteins capable of nonspecific
interactions with AbH5N2@Fe3O4 MNPs. Consequently,
isolation of the viral HA protein by AbH5N2@Fe3O4
MNPs was more efficient in RIPA buffer than in water
or PBS buffer.
MALDI-MS can be combined with a biologically
active probe to rapidly and specifically detect proteins of
interest. To explore the capability of on-MNP readout
by MALDI-MS, a protein pool mimicking a complex
biological medium was prepared in 60 μLo fP B Sc o m -
prising various amounts of the recombinant HA protein
of antigenic H5 type (200 ng, 100 ng and 50 ng) and a
significant excess of other “nonantigenic” proteins such
as transferrin (5 μg), fetuin (5 μg) and ribonuclease (1
μg). The abundance of the HA protein (1.8-0.5%, w/w)
was purposely low to test the extraction efficiency of the
AbH5N2@Fe3O4 MNPs. After enrichment of HA pro-
teins, the HA-MNP complex was mixed with sinapinic
acid (SA), a MALDI matrix, and directly subjected to
MALDI-MS analysis.
Although the antibody-antigen complexes have strong
interactions with dissociation constants (Kd)r a n g i n g
from 10
-7 to 10
-11 M, most antibody-antigen complexes
can still be dissociated at extreme pH (i.e., pH < 2 or
pH > 12). The SA matrix solution used for MALDI-MS
analysis has a low pH (< 2) and thus may directly elute
the antigen bound to the antibody-conjugated MNPs on
the MALDI sample plate.
Prior to affinity extraction (Figure 3A), the MALDI
spectrum of the protein mixture was complex and the
targeted HA was not observed due to its low abundance
and ion suppression. After affinity extraction (Figure
3B), two distinct signals appeared at m/z 75238 and
37607 Da, which were derived from the glycosylated HA
Figure 2 Characterization of the aminosilane-coated iron oxide magnetic nanoparticles AS@Fe3O4 MNP. A transmission electron
microscopy image of AS@Fe3O4 MNP (A), structural characterization by powder X-Ray diffraction spectroscopy (B), and magnetization
characterization by superconducting quantum interference device magnetometer (C).
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+ and [M +
2H]
2+, respectively) [25]. The characteristic broad peak
shape of the glycosylated protein [43-45] could not be
resolved under the mass resolution of our instrument.
The shift of several kDa compared with the theoretical
molecular weight of HA (theoretical average mass ≈ 64
kDa) [43-45] might be attributable to the extensive
glycosylation of HA [25]. When the solution containing
less HA (100 ng) was analyzed, the signal intensity sig-
nificantly decreased and partially overlapped with the
antibody signals to form a doublet mass peak (Figure
3D). After subtraction of the mass spectrum of the anti-
body (Figure 3B), the mass peak occurring at m/z
~75400 Da clearly showed the presence of HA protein.
Figure 3 Detection sensitivity of HA protein (H5 type) after extraction by AbH5N2@Fe3O4 MNP. MALDI mass spectra of (A) protein solution
(60 μL) containing HA (200 ng), ribonuclease (1 mg), fetuin (5 mg) and transferrin (5 mg); (B) background peaks from antibody; (C) extraction by
AbH5N2@Fe3O4 MNP (HA signals at approximate 75 kDa and 37 kDa, corresponding to singly and doubly charged ions); (D) extraction from a
protein solution (60 μL) containing HA (100 ng), ribonuclease (1 mg), fetuin (5 mg) and transferrin (5 mg) by AbH5N2@Fe3O4 MNP; and (E)
extraction from a protein solution (60 μL) containing HA (50 ng), ribonuclease (1 mg), fetuin (5 mg) and transferrin (5 mg) by AbH5N2@Fe3O4
MNP. The arrow indicates the experimental m/z of HA. The blue dotted line indicates the antibody. The HA signals after subtraction of the
antibody signals are shown in the insets of (D) and (E).
Chou et al. Journal of Nanobiotechnology 2011, 9:52
http://www.jnanobiotechnology.com/content/9/1/52
Page 5 of 13The affinity extraction of HA protein from a complex
mixture was very efficient using the antibody-conjugated
MNPs, as even a minute amount (50 ng) of HA protein
was visible (Figure 3E). Assuming full recovery of all the
HA protein (50 ng) present in the solution, the absolute
detection limit was estimated to be 0.7 pmol (9 nM).
To evaluate the efficiency of our detection method, we
investigated the effect of incubation time on HA protein
and antibody-conjugated MNP recognition. After incu-
bation of antibody-conjugated MNPs with HA contain-
ing solution, the amount of remaining HA was
concentrated and measured by MALDI-MS. The time
course of such affinity extraction indicated that > 99%
of HA protein in solution was captured by MNPs within
1 min (Figure 4). Thus, using antibody-conjugated
MNPs for rapid and specific extraction, followed by
direct mass spectrometric analysis for ambiguous read-
out, provides an efficient and accurate assay for HA
protein.
￿ Isolation of HA proteins from a virus sample for
electrophoresis and mass spectrometric analyses
The affinity extraction of H5N2 viruses in allantoic fluid
was also realized using AbH5N2@Fe3O4 MNPs. As
shown in SDS-PAGE analysis, without concentration of
the virus lysate from allantoic fluid, only the abundant
protein NP was observed in H5N2 virus (Figure 5A,
lane 1). Using 2 × RIPA buffer, the AbH5N2@Fe3O4
MNPs selectively isolated the viral HA protein from
allantoic fluid (Figure 5A, lanes 2 and 3). As influenza
HA protein (H0) is composed of two disulfide-linked
polypeptides, HA1 and HA2, the use of a reducing
reagent, like b-mercaptoethanol, in SDS-PAGE analysis
will dissociate the HA protein into the two subunits
HA1 and HA2. After treatment with b-mercaptoethanol,
an electrophoresis band occurring at ~45-50 kDa was
attributable to the glycosylated HA1 protein (Figure 5A,
lanes 2 and 3) [25,43-45]. The band with molecular
mass in the range of 50-60 kDa was ascribed to the pro-
teins of antibody from AbH5N2@Fe3O4 MNPs (Figure
5 A ,l a n e5 ) .A san e g a t i v ec o n t r o l ,w ea l s os y n t h e s i z e d
MEG@Fe3O4 MNPs from aminosilane coated
AS@Fe3O4 MNPs and MEGA without antibody conju-
gation. As expected, SDS-PAGE analysis showed that no
viral protein was trapped by MEG@Fe3O4 MNPs. These
results demonstrated the low background and the lack
of false positives (Figure 5A, lane 4) in the presented
method.
To evaluate the assay sensitivity, AbH5N2@Fe3O4
MNPs (10 μg) were incubated with different amounts
(0.05-1 μL) of the 1000-fold diluted H5N2 virus lysate
(~10
7.8 EID50/mL, Figure 5B). As low as 0.1 μLo fv i r u s
lysate, corresponding to ~10
3.8 EID50 of H5N2 viruses,
was detected by SDS-PAGE using silver staining for
visualization (Figure 5B, line 4).
To further confirm the identity of the captured pro-
tein, the electrophoresis band at ~45 kDa was digested
with trypsin and subjected to LC-MS/MS analysis. Data-
base searching with the Mascot engine confidently iden-
tified eight peptide sequences corresponding to the viral
HA1 protein (Figure 6B). An example MS/MS spectrum
is shown in Figure 6A for the peptide SELEYGNCNTR
Figure 4 Kinetic effect on HA enrichment using AbH5N2@Fe3O4 MNP.T oi n v e s t i g a t et h et i m ec o u r s eo fH Ae x t r a c t i o n ,s u p e r n a t a n tw a s
sampled from a 60-mL reaction after different incubation times (1-30 min). HA remaining in the supernatant was vacuum dried and quantified
by MALDI MS peak intensities.
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282-292 of the HA protein from the H5N2 virus.
￿ Differentiation of influenza virus subtypes
Finally, we evaluated whether the high specificity of
AbH5N2@Fe3O4 MNP could be used to unambiguously
differentiate virus subtypes. Besides the H5N2 virus (A/
Duck/Taiwan/3233/04), three recombinant H5N1
viruses (RG5, RG23, and NIBRG14) were investigated.
All of these influenza viruses belong to the H5 category
of influenza A, but it was expected that the AbH5N2@-
Fe3O4 MNP incorporating the monoclonal antibody spe-
cifically against the H5N2 virus would not have cross-
reactivity with the H5N1 virus subtype. To validate such
detection specificity, the lysates of H5N2 and H5N1
viruses were incubated separately with AbH5N2@Fe3O4
MNPs in 2 × RIPA buffer at 25°C. After magnetic
separation, the pellet was washed with 1 × RIPA buffer
and subjected to MALDI-MS analysis. As shown in Fig-
u r e7 A ,t h eM A L D Im a s ss p e c t r u mo b t a i n e df r o mt h e
on-MNP detection of extracted H5N2 virus (A/Duck/
Taiwan/3233/04) revealed strong signals from viral pro-
teins bound on AbH5N2@Fe3O4 MNP. After subtraction
of the antibody spectrum shown in Figure 7C, the mass
spectrum clearly showed signals for glycosylated HA
together with the relatively abundant NP (56002 ± 10
Da) and M1 (28000 ± 10 Da) proteins from H5N2 virus
(Figure 7B). Gratifyingly, none of the recombinant
H5N1 viruses were trapped by the AbH5N2@Fe3O4
MNP. A representative mass spectrum obtained from a
s c r e e n i n go fH 5 N 1( R G 5 )i ss h o w ni nF i g u r e7 D ,a n d
only antibody signals were observed, confirming highly
specific affinity isolation of H5N2. These data demon-
strated the promising application of AbH5N2@Fe3O4
MNPs to distinguish different subtypes in influenza
virus surveillance.
Conclusions
We have demonstrated a facile method for the detection
of H5N2 influenza virus using aminosilane coated iron
oxide nanoparticles with surface functionalization of
monoclonal antibodies specific to the HA protein in
H5N2. Through simple magnetic separation, the
AbH5N2@Fe3O4 MNPs showed effective isolation of
H5N2 viruses from lysate for direct MALDI-TOF MS
readout without the need for a tedious elution step. The
Figure 5 HA purification performance by AbH5N2@Fe3O4. (A) Lane 1: H5N2 virus (200 ng) prepared from allantoic fluid; Lane 2: isolation of
HA protein after incubation of AbH5N2@Fe3O4 MNP with 1 μg of H5N2 virus lysate; Lane 3: isolation of HA protein after incubation of
AbH5N2@Fe3O4 MNP with 200 ng of H5N2 virus lysate; Lane 4: control experiment using MEG@MNP for incubation with 200 ng of H5N2 virus
lysate; Lane 5: AbH5N2@Fe3O4 MNP only. The antibody signals arise from dissociation of AbH5N2 during SDS-PAGE analysis. (B) Purification
efficiency of AbH5N2@Fe3O4 MNP. SDS-PAGE patterns of AbH5N2@Fe3O4 MNP before and after incubation of AbH5N2@Fe3O4 MNP with H5N2 virus
lysate in 2 × RIPA buffer. Lane 1: H5N2 virus; Lanes 2-5: incubation of AbH5N2@Fe3O4 MNP (2 μL) with 1, 0.5, 0.1 and 0.01 μL of H5N2 virus,
respectively; Lanes 6-9: supernatant of Lanes 2-5.
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4 EID50 by SDS-
PAGE or ~10
3 EID50 by MALDI-TOF MS. Our study
demonstrated that the combined use of antibody-MNPs
and MALDI-MS was suitable for sensitive detection of
influenza viruses. Although the direct quantitative com-
parison of our method with other previously reported
diagnostic methods is difficult because each method
characterizes a specific property of the virus under var-
ious conditions, our present method appears to provide
comparable or better sensitivity in the detection of influ-
enza virus than commercially available kits [8,10]. These
kits have a limit of detection in the range of 10
4.5-10
5.5
TCID50 or 10
4.7 ELD50. Therefore, the method presented
here can be utilized for the rapid screening of virus sub-
types. The overall workflow of our method for influenza
virus detection including virus lysis, magnetic separation
and MALDI-TOF MS measurement can be routinely
completed in one hour. We also demonstrated, for the
first time, that the nanoprobe-based detection unam-
biguously differentiated the H5N2 virus from other clo-
sely related antigenic subtypes of (recombinant) H5N1
viruses in a highly specific manner.
With the automatic readout of MALDI-TOF MS, our
method has the potential for integration into high-
throughput virus assays, suggesting a promising applica-
tion in early and accurate diagnosis of influenza viruses.
Given the increasing use of virus screening assays, our
c u r r e n ta s s a yo f f e r saf l e x i b l ed e s i g nf o ri m m o b i l i z a t i o n
of other virus-specific molecular probes on a nanoparti-
cle surface for diverse applications.
Methods
Materials
All of the chemicals were of reagent grade unless indi-
cated otherwise. Ferrous chloride tetrahydrate
(FeCl2
.4H2O), ferric chloride (FeCl3), tetraethyl
Figure 6 The 45 kDa band in SDS-PAGE was identified as HA protein by LC-MS/MS analysis. (A) An example MS/MS spectrum of the
tryptic peptides at m/z 1341.4837 from HA protein; the peptide fragments of y- and b-ions correspond to the sequence SELEYGNCNTR. (B) The
experimental and calculated molecular masses and Mascot scores of the eight matched sequences.
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(APS), 1-propanol, ammonia solution (28%), and
dimethyl sulfide were purchased from Acros. Suberic
acid bis-N-hydroxysuccinimide ester (DSS), 2-bro-
moethylamine hydrobromide (BEI), sodium carbonate,
silver nitrate, a-cyano-4-hydroxycinnamic acid (CHCA),
and sinapinic acid (SA) were purchased from Sigma-
Aldrich. Formalin, methanol, acetonitrile (HPLC grade),
and trifluoroacetic acid (TFA) were purchased from
Merck. Acetic acid and sodium thiosulfate were pur-
chased from J. T. Baker. All the chemicals were used as
received without further purification. A homemade mag-
net was used in the separation of magnetic nanoparticles.
T h eH Ap r o t e i n so fH 5t y p ew e r ep r e p a r e du s i n gt h e
H5 consensus sequence previously described [46]. The 1
× PBS buffer (pH 7.4, GIBCO) contained NaCl (137
mM), KCl (2.7 mM), KH2PO4 (1.5 mM) and Na2HPO4
(8.1 mM). The 1 × RIPA buffer (pH 8.0) contained Tris-
HCl (50 mM, Amersham Bioscience), NaCl (150 mM),
NP-40 (1%, Calbiochem), sodium deoxycholate (0.5%,
Sigma) and sodium dodecyl sulfate (0.1%, USB). The 2 ×
RIPA buffer (pH 8.0) contained Tris-HCl (50 mM),
NaCl (150 mM), NP-40 (2%), sodium deoxycholate (1%)
and sodium dodecyl sulfate (0.1%). The TEN buffer (pH
7.5) contained Tris-HCl (50 mM, pH 7.5), EDTA (pH
8.0, 1.3 mM) and NaCl (100 mM).
Figure 7 Virus screening by incubation of AbH5N2@Fe3O4 MNP with the lysate of different viruses. The examined viruses (40 μL) include
H5N2 (A/Duck/Taiwan/3233/04) and recombinant H5N1 (RG5, RG23, and NIBRG14). After incubation, only the H5N2 subtype was enriched. (A)
HA, NP and M1 proteins were observed in the MALDI mass spectrum; (B) after subtracting the antibody signals (inset C), the HA, NP and M1
signals were clearly observed with good signal-to-noise ratio. For other viruses, only antibody signals were observed. A representative mass
spectrum obtained from screening of RG5 is shown in (D).
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Transmission electron microscopy (TEM) images were
obtained on a Hitachi H-7100 Transmission Electron
Microscope. Powder X-Ray Diffraction (XRD) was
recorded by PANalytical X’ Pert PRO. The magnetic
effect was measured on a superconducting quantum
interference device magnetometer (SQUID, Quantum
Design MPMS7). LC-MS/MS spectra were recorded on
a Waters Q-TOF™ Premier mass spectrometer (Waters
Corp, Milford, MA). MALDI-TOF MS analyses were
performed using an Applied Biosystems 4800 mass spec-
trometer (Applied Biosystems, Foster City, USA)
equipped with a Nd-YAG laser (355 nm).
￿ Preparation of virus
The supernatant (0.2 mL/egg) of H5N2 influenza virus
A/duck/Yunlin/04 (H5N2) was inoculated to the allan-
toic cavity of 9 to 11-day-old specific pathogen-free
(SPF) embryonated hens’ eggs, which were then culti-
vated in an incubator. The eggs that died within 24 h
were discarded. Other eggs were incubated at 4°C for
another 4 h to contract blood vessels. The allantoic fluid
was then collected by needle and stored at -80°C.
To separate the cell lysate, the allantoic fluid was fro-
zen and thawed several times to rupture the cells. The
solution was subjected to centrifugation (3000 rpm,
Centrifuge 5804R, Eppendorf, Germany) at 4°C for 15
min. The supernatant was treated with 1% BEI at 37°C
for 18 h to inactivate the virus. After centrifugation (70,
000 × g, Avanti J-25 Centrifuge, Beckman) at 4°C, the
virus pellets were collected, dissolved in TEN buffer,
and stored overnight at 4°C. The virus was then sepa-
rated by centrifugation (50, 000 rpm, Optima MAX-E
Ultracentrifuge, Beckman) in a sucrose gradient (20-
50%) at 4°C for 2 h. The concentrated H5N2 virus solu-
tion in TEN buffer was estimated to have an EID50 (50%
egg infectious dose) value of about 10
10.8 per mL, corre-
sponding to ~10
11 particles/mL estimated using the
TEM-imaging of a mixture of viruses and a known con-
centration of polystyrene latex beads (137 nm in dia-
meter) [47].
The recombinant H5N1 viruses RG5 (A/Anhui/1/
2005), RG23 (A/turkey/Turkey/01/2003) and NIBRG14
(A/Vietnam/1194/2004) were obtained from Dr. Jia-
Tsrong Jan (The Genomics Research Center, Academia
Sinica) [46]. The TCID50 (50% tissue culture infectious
dose) on Madin-Darby canine kidney (MDCK) cells was
estimated to be around 3 × 10
6 (RG5), 1 × 10
5 (RG23),
and 3 × 10
6 (NIBRG14) per mL, respectively, according
to the Reed-Muench method [48].
￿ Preparation of antibody
The monoclonal antibodies against A/duck/Yunlin/04
(H5N2) virus were purchased from LTK BioLaboratories
(Taipei, Taiwan) and purified on an immunoglobin affi-
nity column. Briefly, a protein A HiTrap affinity column
(Pharmacia biotech, Orsay, France) was activated with
binding buffer (20 mM sodium phosphate buffer, pH
7.0). The ascites (1 mL) were mixed with Tris-HCl (200
μL of 1 M solution, pH 9.0) and applied to the affinity
column. After the turbid impurities were washed off
with binding buffer (10 × column volume), a striping
buffer (700 μL of 0.1 M citric acid, pH 3.0) was applied
to elute the antibodies. The collected antibody solution
was then dialyzed in 1 L of PBS buffer (0.1 M) and
stored at -20°C. The content of antibody protein (3 ×
10
3 μg/mL) was measured by the Bradford method [49].
￿ Preparation of aminosilane coated iron oxide magnetic
nanoparticles
Iron oxide nanoparticles (Fe3O4) were synthesized using
FeCl2 and FeCl3 under basic conditions according to the
previously reported method [40]. The freshly prepared
Fe3O4 nanoparticles (30 mg) were suspended in 1-pro-
panol (80 mL) and sonicated for 40 min at room tem-
perature. Next, NH4OH (28% w/w, 8.94 mL), ddH2O
(7.5 mL), and TEOS (0.1 mL) were slowly added to the
above solution, and the mixture was stirred at 40°C for
2 h. APS (0.1 mL) was injected into the solution and the
mixture was stirred for another 1 h. The blackish preci-
pitates were collected with a magnet and washed with
1-propanol to give the aminosilane coated iron oxide
magnetic nanoparticles (AS@Fe3O4 MNP).
￿ Synthesis of antibody conjugated magnetic nanoparticles
AS@Fe3O4 MNPs (0.5 mg) were suspended in DMSO
(125 μL) and sonicated for 30 min at room temperature.
DSS (5 mg) was added to the solution and the mixture
was stirred at room temperature for 1 h. The precipi-
tates were separated by magnet and washed with
DMSO (250 μL) three times. The antibody (15 μL) was
added at 4°C. After 1 h, a blocking reagent, 3, 6, 9-
trioxadecylamine (a methoxy-terminated ethylene glycol
amine, MEGA, 35 μLo f3 0m Ms o l u t i o ni nD M S O ) ,
was added to the mixture. The mixture was stirred for
another 18 h at 4°C, and the precipitates were collected
by magnet. After washing with PBS, the antibody conju-
gated nanoparticles (AbH5N2@Fe3O4 MNP) were re-dis-
solved in PBS (50 μL) and stored at 4°C. By a similar
procedure but without the addition of antibody, the
ethylene glycol encapsulated nanoparticles MEGA@-
Fe3O4 MNP were prepared and used as the control in
experiments.
￿ Incubation of AbH5N2@Fe3O4 MNP with viruses
Concentrated H5N2 virus solution (2 μLo f1 . 0 3×1 0
3
μg/mL in TEN buffer) was incubated with 2 × RIPA
buffer (57 μL) at 25°C for 1 h. An aliquot (1 μL) of
AbH5N2@Fe3O4 MNP (0.5 mg in 50 μLo f1×P B S )w a s
added to the virus solution and incubated for 30 min.
The HA-MNP complexes were then isolated by magnet
and washed with 1 × RIPA buffer for the subsequent
SDS-PAGE and MALDI-TOF MS analyses.
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The above-prepared HA-MNP complexes were resus-
pended in sample buffer containing 50 mM Tris-HCl
(pH 6.8), SDS (1%, w/v), glycerol (10%, v/v), bromophe-
nol blue (0.01%, w/v), and 0.7 M b-mercaptoethanol,
a n dt h e nh e a t e da t9 5 ° Cf o r5m i n .T h es a m p l ew a s
then separated on 10% SDS-PAGE gel in a running buf-
fer containing Tris (0.3%, w/v), glycine (1.2%, w/v) and
SDS (0.1%, w/v). Visualization of the protein bands was
performed by silver staining. The SDS-PAGE was fixed
with a solution containing 50% methanol, 12% acetic
acid and 0.05% formalin for at least 2 h. The gel was
washed three times with 35% ethanol for 20 min and
soaked in a sensitizer solution (0.02% sodium thiosul-
fate) for 2 min. The gel was washed three times with
deionized water and then incubated with a staining buf-
fer containing silver nitrate (0.2%, w/v) and formalin
(0.076%) in the dark for 20 min. The gel was then
washed twice with deionized water. The band images
were developed in a 50 mL solution containing sodium
carbonate (6%, w/v), sodium thiosulfate (0.0004%, w/v)
and formalin (0.05%). The silver reduction was pro-
cessed for about 2 min until the expected intensity of
protein was reached. Image development was terminated
by treatment with a stop solution containing acetic acid
(12%) and methanol (50%) for 5 min, then stored at 4°C
in 1% acetic acid.
￿ Protein digestion and LC-MS/MS analysis
After electrophoresis, the band at ~45 kDa, correspond-
ing to the HA1 protein, was taken from the SDS-PAGE
gel and cut into small pieces (1 mm
3). The gel slices
were washed with 25 mM ammonium bicarbonate and
50% acetonitrile, reduced with 10 mM dithiothreitol,
and then alkylated with 55 mM iodoacetamide. Trypsin
(protein/trypsin = 20:1, g/g) was used to digest the pro-
tein by incubation for 12 h at 37°C. The resulting pep-
tides were extracted with acetonitrile/TFA (50%/0.1%)
and then acetonitrile. The peptide solution was concen-
trated on a SpeedVac and reconstituted in 8 L of 0.1%
TFA aqueous solution (buffer A).
For protein identification by LC-MS/MS, the digested
peptides were injected into a capillary trap column (2
cm × 180 μm) and separated on a BEH C18 column (25
cm × 75 mm × 1.7 mm, Waters ACQUITY, Milford,
MA). The column was maintained at 35°C and the
bound peptides were eluted with a linear gradient of 0-
80% buffer B/A (buffer A, 0.1% TFA in H2O; buffer B,
0.1% TFA in acetonitrile) for 80, 120, 180, 210 and 270
minutes. MS was operated in ESI positive V mode with
a resolving power of 10, 000. NanoLockSpray source
was used for accurate mass measurement and the lock
mass channel was sampled every 30 seconds. The mass
spectrometer was calibrated with a synthetic human
[Glu
1]-Fibrinopeptide B solution (1 pmol/μL, from
Sigma-Aldrich) delivered through the NanoLockSpray
source. Data acquisition was operated in the data direc-
ted analysis (DDA) mode. The method included a full
MS scan (m/z 400-1600, 0.6 seconds) and three MS/MS
scans (m/z 100-1990, 1.2 seconds each scan) sequentially
o nt h et h r e em o s ti n t e n s ei o n sp r e s e n ti nt h ef u l ls c a n
mass spectrum. The identification of peptide sequences
was performed by database searching of MS/MS spectra
using the Mascot algorithm (v2.1.0, Matrix Science,
London, UK) against the NCBI database. The peak lists
in the MS/MS spectra were extracted from Analyst QS
1.1 (Applied Biosystems) software with the default
charge state set to 2+, 3+, and 4+. Search parameters
for peptide and MS/MS mass tolerance were ± 0.3 and
± 0.1 Da, respectively, with allowance for two missed
cleavages from the trypsin digest and variable modifica-
tions of carbamidomethyl (Cys) and oxidation (Met).
Peptides were considered confidently identified if their
Mascot individual ion scores were higher than the Mas-
cot identity scores (p < 0.05).
￿ MALDI-TOF MS analysis
The sample of H5N2 virus enriched by trapping with
AbH5N2@Fe3O4 MNPs was mixed with fresh sinapinic
acid (10 g/L) in a 1:1 (v/v) ratio. The complex was
directly deposited onto the sample plate, dried in air,
and then subjected to analysis on a 4800 MALDI TOF/
TOF MALDI-TOF/TOF mass spectrometer (Applied
Biosystems, Foster City, CA). To obtain a stable signal, a
typical mass spectrum was constructed by averaging
1800 laser shots followed by noise reduction and Gaus-
sian smoothing using Data-Explorer software (Applied
Biosystems). The MALDI-TOF MS analysis was
acquired with an Nd-YAG laser (355 nm) operating at a
repetition rate of 200 Hz. The spectra were recorded in
the linear mode using an accelerating voltage of 20 kV,
a 19% grid voltage, a low-mass gate of 10 kDa, and a
630 ns delay time. The protein mixture of cytochrome c
(12361 Da) and myoglobin (16952 Da) was used as an
external mass calibration reference.
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